Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade B 59.86 -0.23% -0.14
RETA closed down 0.23 percent on Friday, November 16, 2018, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical RETA trend table...

Date Alert Name Type % Chg
Nov 16 20 DMA Resistance Bearish 0.00%
Nov 16 Doji - Bullish? Reversal 0.00%
Nov 16 Multiple of Ten Bearish Other 0.00%
Nov 16 Outside Day Range Expansion 0.00%
Nov 16 Down 3 Days in a Row Weakness 0.00%
Nov 16 Down 4 Days in a Row Weakness 0.00%
Nov 16 Down 5 Days in a Row Weakness 0.00%
Nov 15 20 DMA Resistance Bearish -0.23%
Nov 15 Narrow Range Bar Range Contraction -0.23%
Nov 15 NR7 Range Contraction -0.23%

Older signals for RETA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 99.5
52 Week Low 19.31
Average Volume 298,024
200-Day Moving Average 47.5084
50-Day Moving Average 70.3713
20-Day Moving Average 61.0985
10-Day Moving Average 63.714
Average True Range 4.7544
ADX 23.74
+DI 15.6093
-DI 17.86
Chandelier Exit (Long, 3 ATRs ) 58.9068
Chandelier Exit (Short, 3 ATRs ) 67.7832
Upper Bollinger Band 69.4954
Lower Bollinger Band 52.7016
Percent B (%b) 0.43
BandWidth 27.486436
MACD Line -1.5106
MACD Signal Line -1.7842
MACD Histogram 0.2736
Fundamentals Value
Market Cap 1.56 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -56.47
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 64.87
Resistance 3 (R3) 65.04 63.54 64.04
Resistance 2 (R2) 63.54 62.26 63.46 63.76
Resistance 1 (R1) 61.70 61.48 60.95 61.53 63.48
Pivot Point 60.20 60.20 59.83 60.12 60.20
Support 1 (S1) 58.36 58.92 57.61 58.19 56.24
Support 2 (S2) 56.86 58.14 56.78 55.96
Support 3 (S3) 55.02 56.86 55.69
Support 4 (S4) 54.85